Recent Development of LDL-Based Nanoparticles for Cancer Therapy

Overview

Journal Pharmaceuticals (Basel)

Publisher MDPI

Specialty Chemistry

Date 2023 Jan 21

PMID 36678515

Authors

Binghong He

Qiong Yang

Affiliations

Soon will be listed here.

Abstract

Low-density lipoprotein (LDL), a natural lipoprotein transporting cholesterol in the circulatory system, has been a possible drug carrier for targeted delivery. LDL can bind to the LDL receptor (LDLR) with its outside apolipoprotein B-100 and then enter the cell via LDLR-mediated endocytosis. This targeting function inspires researchers to modify LDL to deliver different therapeutic drugs. Drugs can be loaded in the surficial phospholipids, hydrophobic core, or apolipoprotein for the structure of LDL. In addition, LDL-like synthetic nanoparticles carrying therapeutic drugs are also under investigation for the scarcity of natural LDL. In addition to being a carrier, LDL can also be a targeting molecule, decorated to the surface of synthetic nanoparticles loaded with cytotoxic compounds. This review summarizes the properties of LDL and the different kinds of LDL-based delivery nanoparticles, their loading strategies, and the achievements of the recent anti-tumor advancement.

Citing Articles

Application of Nanomaterials in Early Imaging and Advanced Treatment of Atherosclerosis.

Zhou Q, Wang Y, Si G, Chen X, Mu D, Zhang B Chem Biomed Imaging. 2025; 3(2):51-76.

PMID: 40018650 PMC: 11863161. DOI: 10.1021/cbmi.4c00064.

Anti-inflammatory Therapies for Ischemic Heart Disease.

Muhs T, Ljubojevic-Holzer S, Sattler S Curr Cardiol Rep. 2025; 27(1):57.

PMID: 39969632 PMC: 11839821. DOI: 10.1007/s11886-025-02211-0.

Docosahexaenoic acid-loaded nanoparticles: A state-of-the-art of preparation methods, characterization, functionality, and therapeutic applications.

Ali A, Hachem M, Ahmmed M Heliyon. 2024; 10(9):e30946.

PMID: 38774069 PMC: 11107210. DOI: 10.1016/j.heliyon.2024.e30946.

References

Qian J, Xu N, Zhou X, Shi K, Du Q, Yin X . Low density lipoprotein mimic nanoparticles composed of amphipathic hybrid peptides and lipids for tumor-targeted delivery of paclitaxel. Int J Nanomedicine. 2019; 14:7431-7446. PMC: 6751769. DOI: 10.2147/IJN.S215080. View

Baillie G, Owens M, Halbert G . A synthetic low density lipoprotein particle capable of supporting U937 proliferation in vitro. J Lipid Res. 2002; 43(1):69-73. View

Wicki A, Witzigmann D, Balasubramanian V, Huwyler J . Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2014; 200:138-57. DOI: 10.1016/j.jconrel.2014.12.030. View

Ye J, Zhang R, Chai W, Du X . Low-density lipoprotein decorated silica nanoparticles co-delivering sorafenib and doxorubicin for effective treatment of hepatocellular carcinoma. Drug Deliv. 2019; 25(1):2007-2014. PMC: 6319454. DOI: 10.1080/10717544.2018.1531953. View

Zhu C, Pradhan P, Huo D, Xue J, Shen S, Roy K . Reconstitution of Low-Density Lipoproteins with Fatty Acids for the Targeted Delivery of Drugs into Cancer Cells. Angew Chem Int Ed Engl. 2017; 56(35):10399-10402. PMC: 6554211. DOI: 10.1002/anie.201704674. View

Tabernero J, Shapiro G, LoRusso P, Cervantes A, Schwartz G, Weiss G . First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013; 3(4):406-17. DOI: 10.1158/2159-8290.CD-12-0429. View

Taskinen M . LDL-cholesterol, HDL-cholesterol or triglycerides--which is the culprit?. Diabetes Res Clin Pract. 2003; 61 Suppl 1:S19-26. DOI: 10.1016/s0168-8227(03)00126-8. View

Jeon H, Blacklow S . Structure and physiologic function of the low-density lipoprotein receptor. Annu Rev Biochem. 2005; 74:535-62. DOI: 10.1146/annurev.biochem.74.082803.133354. View

Chu A, Tsang S, Lo E, Fung K . Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2002; 70(5):591-601. DOI: 10.1016/s0024-3205(01)01441-2. View

10.

Li C, Zhang J, Wu H, Li L, Yang C, Song S . Lectin-like oxidized low-density lipoprotein receptor-1 facilitates metastasis of gastric cancer through driving epithelial-mesenchymal transition and PI3K/Akt/GSK3β activation. Sci Rep. 2017; 7:45275. PMC: 5366889. DOI: 10.1038/srep45275. View

11.

Xu X, Wang L, Xu H, Huang X, Qian Y, Xiang J . Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. Asian Pac J Cancer Prev. 2013; 14(4):2591-4. DOI: 10.7314/apjcp.2013.14.4.2591. View

12.

Caruso M, Notarnicola M, Cavallini A, Guerra V, Misciagna G, Di Leo A . Demonstration of low density lipoprotein receptor in human colonic carcinoma and surrounding mucosa by immunoenzymatic assay. Ital J Gastroenterol. 1993; 25(7):361-7. View

13.

Huntosova V, Buzova D, Petrovajova D, Kasak P, Nadova Z, Jancura D . Development of a new LDL-based transport system for hydrophobic/amphiphilic drug delivery to cancer cells. Int J Pharm. 2012; 436(1-2):463-71. DOI: 10.1016/j.ijpharm.2012.07.005. View

14.

McConathy W, Paranjape S, Mooberry L, Buttreddy S, Nair M, Lacko A . Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv Transl Res. 2015; 1(2):113-20. DOI: 10.1007/s13346-010-0012-0. View

15.

Reynolds L, Mulik R, Wen X, Dilip A, Corbin I . Low-density lipoprotein-mediated delivery of docosahexaenoic acid selectively kills murine liver cancer cells. Nanomedicine (Lond). 2014; 9(14):2123-41. PMC: 4156561. DOI: 10.2217/nnm.13.187. View

16.

Zhu W, Yang S, Qu C, Zhu Q, Chen W, Li F . Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor. Int J Nanomedicine. 2017; 12:3375-3393. PMC: 5413542. DOI: 10.2147/IJN.S126310. View

17.

Lee J, Kim J, Bae K, Oh M, Kim Y, Kim J . Low-density lipoprotein-mimicking nanoparticles for tumor-targeted theranostic applications. Small. 2014; 11(2):222-31. DOI: 10.1002/smll.201303277. View

18.

Krieger M, Goldstein J, Brown M . Receptor-mediated uptake of low density lipoprotein reconstituted with 25-hydroxycholesteryl oleate suppresses 3-hydroxy-3-methylglutaryl-coenzyme A reductase and inhibits growth of human fibroblasts. Proc Natl Acad Sci U S A. 1978; 75(10):5052-6. PMC: 336261. DOI: 10.1073/pnas.75.10.5052. View

19.

Su H, Li X, Liang D, Qi X . Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity. Oncotarget. 2016; 7(32):51535-51552. PMC: 5239495. DOI: 10.18632/oncotarget.10493. View

20.

An X, Zhu A, Luo H, Ke H, Chen H, Zhao Y . Rational Design of Multi-Stimuli-Responsive Nanoparticles for Precise Cancer Therapy. ACS Nano. 2016; 10(6):5947-58. DOI: 10.1021/acsnano.6b01296. View